Preliminary data from two recent Phase III clinical trials to assess the efficacy of ViRexx's OvaRex as a maintenance treatment for advanced ovarian cancer have failed to show any difference in patients treated with the drug when compared to patients who did not receive treatment. The failure of OvaRex, an immunotherapy, in the IMPACT-I and -II trials involving 367 women with advanced ovarian cancer, represents one of several immunotherapies which have not proven efficacious as maintenance therapies for ovarian cancer in trials.

As a result of this breaking news, the findings and market forecast of Decision Resources' upcoming Ovarian Cancer report will reflect the most up- to-date information available in the ovarian cancer drug market. The author of the report, Decision Resources Analyst Mohamed Muhsin, is available to comment on the market impact of OvaRex's Phase III clinical trial results.

  For those reporters covering this topic, Mr. Muhsin can discuss:    -- What impact will OvaRex's clinical trial failure have on the ovarian      cancer drug market?    -- Why have OvaRex and other immunotherapies failed to show efficacy in      ovarian cancer?    -- The opinions of interviewed clinicians regarding the future of      immunotherapy treatment for ovarian cancer.    -- Which drugs are currently driving the ovarian cancer drug market and      which emerging agents will spur growth over the next decade.   

To speak with Mr. Muhsin, please contact Liz Marshall at 781-296-2563 or

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

PRNewswire -- Dec. 10
First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

Ankylosing Spondylitis Drug Market Will Reach $661 Million in 2016

View Now